Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study [0.03%]
针对HER2表达的转移性乳腺癌或尿路上皮癌患者中T-DXd联合纳武利尤单抗治疗的Ib期研究（DS8201-A-U105）的分析
Erika Hamilton,Matthew D Galsky,Sebastian Ochsenreither et al.
Erika Hamilton et al.
Purpose: This multicenter phase Ib study investigated trastuzumab deruxtecan (T-DXd) plus nivolumab in patients with HER2-expressing metastatic breast cancer (mBC) and metastatic urothelial cancer (mUC). ...
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma [0.03%]
仑伐替尼联合派姆单抗治疗肉瘤的病理特征特异性临床试验研究
Sujana Movva,Kenneth Seier,Viswatej Avutu et al.
Sujana Movva et al.
Purpose: Survival of patients with metastatic sarcoma remains poor, and there is a pressing need for new therapies. Most sarcoma subtypes are not responsive to immune checkpoint inhibition alone. Lenvatinib, a multirecept...
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas [0.03%]
FDA批准概要：Polatuzumab Vedotin用于选择性大B细胞淋巴瘤的一线治疗
Maryam Sarraf Yazdy,Yvette L Kasamon,Wenjuan Gu et al.
Maryam Sarraf Yazdy et al.
In April 2023, the U.S. FDA granted regular approval to polatuzumab vedotin-piiq in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (pola+R-CHP) for adult patients who have previously untreated diffuse la...
Tissue-Resident T Cells in Clinical Response and Immune-Related Adverse Events of Immune Checkpoint Blockade [0.03%]
免疫检查点抑制剂治疗的临床疗效和药物相关不良事件中的组织定居T细胞的作用
Ye Zhao,Kai W Wucherpfennig
Ye Zhao
T-cell surveillance of tissues is spatially organized: circulating memory T cells perform surveillance of secondary lymphoid organs, whereas tissue-resident memory T cells act as sentinels in barrier tissues. In the context of infection, ti...
Retraction: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance [0.03%]
撤稿：CD44表达代表了一部分胃癌细胞群体，刺猬信号传导促进化疗耐药性
Changhwan Yoon,Do Joong Park,Benjamin Schmidt et al.
Changhwan Yoon et al.
Editor's Note: Tumor Escape from Endogenous, Extracellular Matrix-Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors [0.03%]
编者按：肿瘤通过上调多种促血管生成因子逃避免疫系统中的内源性、细胞外基质相关血管生成抑制物的作用
Namali T Fernando,Moritz Koch,Courtney Rothrock et al.
Namali T Fernando et al.
Retraction: KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition [0.03%]
撤稿：KMT2C突变通过促进上皮间质转化促进弥漫型胃腺癌发展
Soo-Jeong Cho,Changhwan Yoon,Jun Ho Lee et al.
Soo-Jeong Cho et al.
Retraction: Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells [0.03%]
撤稿：癌干细胞样细胞活化的RhoA介导弥漫型胃腺癌的化疗耐药性
Changhwan Yoon,Soo-Jeong Cho,Bülent Arman Aksoy et al.
Changhwan Yoon et al.
DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies [0.03%]
DICER1相关肿瘤易感：高危个体识别及推荐监测策略
Kris Ann P Schultz,Alexander T Nelson,Paige H R Mallinger et al.
Kris Ann P Schultz et al.
Purpose: DICER1-related tumor predisposition increases risk for a spectrum of benign and malignant tumors. In 2018, the International Pleuropulmonary Blastoma (PPB)/DICER1 Registry published guidelines for testing- and im...
Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer [0.03%]
抗IL1RAP抗体Nadunolimab（CAN04）联合吉西他滨和白蛋白结合型紫杉醇治疗晚期/转移性胰腺癌的疗效和安全性
Eric Van Cutsem,Joelle Collignon,Rikke L Eefsen et al.
Eric Van Cutsem et al.
Purpose: IL1 pathway upregulation is implicated in pancreatic ductal adenocarcinoma (PDAC) progression, therapy resistance, and survival. Nadunolimab is an IL1 receptor accessory protein (IL1RAP)-targeting antibody with e...